Lewis Karen 4
4 · Apellis Pharmaceuticals, Inc. · Filed Apr 5, 2023
Insider Transaction Report
Form 4
Lewis Karen
Chief People Officer
Transactions
- Exercise/Conversion
Common Stock
2023-04-03$34.11/sh+5,000$170,550→ 46,430 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-04-03−5,000→ 111,000 totalExercise: $34.11Exp: 2030-05-03→ Common Stock (5,000 underlying) - Sale
Common Stock
2023-04-03$75.00/sh−5,000$375,000→ 41,430 total
Footnotes (2)
- [F1]This is a scheduled exercise and sale from an established 10b5-1 plan.
- [F2]This stock option was granted on 5/4/2020 and has a four year vesting period. 25% vest one year from grant date. The remaining 75% vest monthly over the last three years of the four year vesting period.